Surgical specimen can be replaced by core samples in assessment of ER, PR and HER-2 for invasive breast cancer

References

• Parker SH, Lovin JD, Jobe WE, Luethke JM, Hopper KD, Yakes WF, et al. Stereotactic breast biopsy with a biopsy gun. Radiology 1990; 176: 741–7
   PubMed Web of Science ®Google Scholar
• Verkooijen HM, Peeters PH, Buskens E, Koot VC, Borel Rinkes IH, Mali WP, et al. Diagnostic accuracy of large-core needle biopsy for nonpalpable breast disease: A meta-analysis. Br J Cancer 2000; 82: 1017–21
   PubMed Web of Science ®Google Scholar
• Denley H, Pinder SE, Elston CW, Lee AH, Ellis IO. Preoperative assessment of prognostic factors in breast cancer. J Clin Pathol 2001; 54: 20–4
   PubMed Web of Science ®Google Scholar
• Douglas-Jones AG, Collett N, Morgan JM, Jasani B. Comparison of core oestrogen receptor (ER) assay with excised tumour: Intratumoral distribution of ER in breast carcinoma. J Clin Pathol 2001; 54: 951–5
   PubMed Web of Science ®Google Scholar
• Mueller-Holzner E, Fink V, Frede T, Marth C. Immunohistochemical determination of HER2 expression in breast cancer from core biopsy specimens: A reliable predictor of HER2 status of the whole tumor. Breast Cancer Res Treat 2001; 69: 13–9
   PubMed Web of Science ®Google Scholar
• Lake DE, Hudis C. Aromatase inhibitors in breast cancer: An update. Cancer Control. 2002; 9: 490–8
   PubMedGoogle Scholar
• Coleman RE. Current and future status of adjuvant therapy for breast cancer. Cancer 2003; 97: 880–6
   PubMed Web of Science ®Google Scholar
• Bhargava R, Lal P, Chen B. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: Does it measure up to fluorescence in situ hybridization?. Am J Clin Pathol 2005; 123: 237–43
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177–82
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659–72
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673–84
   PubMed Web of Science ®Google Scholar
• Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809–20
   PubMed Web of Science ®Google Scholar
• Zidan A, Christie Brown JS, Peston D, Shousha S. Oestrogen and progesterone receptor assessment in core biopsy specimens of breast carcinoma. J Clin Pathol 1997; 50: 27–9
   PubMed Web of Science ®Google Scholar
• Connor CS, Tawfik OW, Joyce AJ, Davis MK, Mayo MS, Jewell WR. A comparison of prognostic tumor markers obtained on image-guided breast biopsies and final surgical specimens. Am J Surg 2002; 184: 322–4
   PubMed Web of Science ®Google Scholar
• Badoual C, Maruani A, Ghorra C, Lebas P, Avigdor S, Michenet P. Pathological prognostic factors of invasive breast carcinoma in ultrasound-guided large core biopsies-correlation with subsequent surgical excisions. Breast 2005; 14: 22–7
   PubMed Web of Science ®Google Scholar
• Mann GB, Fahey VD, Feleppa F, Buchanan MR. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol 2005; 23: 5148–54
   PubMed Web of Science ®Google Scholar
• Becker L, Taves D, McCurdy L, Muscedere G, Karlik S, Ward S. Stereotactic core biopsy of breast microcalcifications: Comparison of film versus digital mammography, both using an add-on unit. AJR Am J Roentgenol 2001; 177: 1451–7
   PubMed Web of Science ®Google Scholar
• Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474–81
   PubMed Web of Science ®Google Scholar
• Bankfalvi A, Simon R, Brandt B, Burger H, Vollmer I, Dockhorn-Dworniczak B, et al. Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use. Histopathology 2000; 37: 411–9
   PubMed Web of Science ®Google Scholar
• Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, et al. Current perspectives on HER2 testing: A review of national testing guidelines. Mod Pathol 2003; 16: 173–82
   PubMed Web of Science ®Google Scholar
• Liberman L, Dershaw DD, Rosen PP, Abramson AF, Deutch BM, Hann LE. Stereotaxic 14-gauge breast biopsy: How many core biopsy specimens are needed?. Radiology 1994; 192: 793–5
   PubMed Web of Science ®Google Scholar